Bausch Health Companies Inc. (BHC): Price and Financial Metrics
Bausch Health Companies Inc. (BHC)
Today's Latest Price: $18.58 USD
Updated May 28 8:04pm
Add BHC to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 214 in Medical - Pharmaceuticals
See all "A" rated Strong Buy stocks
BHC Stock Summary
- The capital turnover (annual revenue relative to shareholder's equity) for BHC is 11.96 -- better than 97.36% of US stocks.
- Equity multiplier, or assets relative to shareholders' equity, comes in at 18.9 for Bausch Health Companies Inc; that's greater than it is for 98.38% of US stocks.
- Over the past twelve months, BHC has reported earnings growth of -435.63%, putting it ahead of merely 3.97% of US stocks in our set.
- If you're looking for stocks that are quantitatively similar to Bausch Health Companies Inc, a group of peers worth examining would be CNR, GTT, COMM, SEAS, and NNBR.
- BHC's SEC filings can be seen here. And to visit Bausch Health Companies Inc's official web site, go to www.bauschhealth.com.
BHC Stock Price Chart More Charts
BHC Price/Volume Stats
| Current price | $18.58 | 52-week high | $31.97 |
| Prev. close | $18.52 | 52-week low | $11.15 |
| Day low | $18.22 | Volume | 7,139,500 |
| Day high | $18.93 | Avg. volume | 5,455,711 |
| 50-day MA | $16.40 | Dividend yield | N/A |
| 200-day MA | $22.92 | Market Cap | 6.54B |
Bausch Health Companies Inc. (BHC) Company Bio
Bausch Health Cos. Inc. (formerly) Valeant Pharmaceuticals is engaged in developing, manufacturing, and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter products, and medical devices, including contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices. The company was founded in 1983 and is based in Laval, Canada.
BHC Price Forecast Based on DCF Valuation
| Current Price | DCF Fair Value Target: | Forecasted Gain: |
| $18.58 | $8.22 | -55% |
Below please find a table outlining a discounted cash flow forecast for BHC, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that Bausch Health Companies Inc ranked in the 27th percentile in terms of potential gain offered. We should note, though, that the most conservative analysis suggests this stock will yield negative results -- and thus may be a potential short opportunity. The most interesting components of our discounted cash flow analysis for Bausch Health Companies Inc ended up being:
- In the past 5.77 years, Bausch Health Companies Inc has a compound free cash flow growth rate of 0.01%; that's higher than just 20.99% of free cash flow generating stocks in the Healthcare sector.
- 21% of the company's capital comes from equity, which is greater than merely 9.48% of stocks in our cash flow based forecasting set.
- Bausch Health Companies Inc's interest coverage rate -- a measure of gross earnings relative to interest payments -- comes in at -0.18. This coverage rate is greater than that of merely 20.18% of stocks we're observing for the purpose of forecasting via discounted cash flows.
| Terminal Growth Rate in Free Cash Flow | Return Relative to Current Share Price |
| 0% | -56% |
| 1% | -55% |
| 2% | -55% |
| 3% | -54% |
| 4% | -54% |
| 5% | -53% |
ZBH, ABT, BIO, ENZ, and TMO can be thought of as valuation peers to BHC, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.
Loading social stream, please wait...